TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15319158
Drug: Finasteride 0.2
Normalized name: MINOXIDIL 5 g in 100 g / FINASTERIDE 0.25 g in 100 g TOPICAL AEROSOL, FOAM [JOHNSON FOAM PRO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 0.2 mg
Study: 28803386
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg/day (n=60)
Study: 28803386
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy alone (n=64)
Study: 21842454
Drug: No orthopedic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No orthopedic treatment (control group)
Study: 17555465
Drug: Sirolimus (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (n = 30; dosed to maintain trough concentrations of 10‐25 ng ml(‐1) until week 8, and then 8‐15 ng ml(‐1) thereafter) in combination with daclizumab, oral MMF and corticosteroids
Study: 17555465
Drug: Ciclosporin (CsA)
Normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ciclosporin (CsA) (n = 15; administered as per centre practice) in combination with daclizumab, oral MMF and corticosteroids
Study: 15104606
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg of oral misoprostol
Study: 9010987
Drug: Granisetron (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (combined doses)
Study: 7944533
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral flucloxacillin
Study: 7944533
Drug: Antibiotics when
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics when clinically indicated
Study: 289417
Drug: Prophylactic metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic metronidazole (Flagyl) 200 mg every 8 hours for 3 days
Study: 23808185
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of mexidol 300 mg and picamilon 150 mg
Study: 19442782
Drug: 600 mcg
Normalized name: Biotin 600 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mcg oral misoprostol
Study: 23697561
Drug: 400 mcg
Normalized name: Biotin 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg sublingual misoprostol
Study: 17141985
Drug: New amoxicillin/clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: New amoxicillin/clavulanate therapeutic system (1500 mg amoxicillin and 125 mg clavulanic acid)
Study: 14732656
Drug: Verteporfin PDT
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin PDT with 14 mg/m² infusion followed by red light exposure at 180 J/cm²
Study: 11558864
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g
Study: 11558864
Drug: Ampicillin/sulbactam 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin/sulbactam 3 g
Study: 9577289
Drug: Ranitidine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine treatment
Study: 31897548
Drug: Low-dose (3-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose (3-7 spheroids/cm2)
Study: 31897548
Drug: Medium-dose (10-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose (10-30 spheroids/cm2)
Study: 31897548
Drug: High-dose (40-70
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (40-70 spheroids/cm2)
Study: 25643127
Drug: Onabotulinumtoxin A
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Onabotulinumtoxin A injections
Study: 12803593
Drug: Lignocaine 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 5% ointment (n = 50)
Study: 1310916
Drug: Steady-state mild
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steady-state mild hypothermia (rectal temperature 33.9 +/- 0.7 degrees C)
Study: 6147293
Drug: Somatostatin at
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin at a dose of 250 micrograms/h in saline (n = 12)
Study: 24531238
Drug: Early rehabilitation
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early rehabilitation interventions including consultation with a rehabilitation physician, pain management, physiotherapy, psychological treatment, and further specialist referrals
Study: 7636819
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (5 minutes application)
Study: 1968739
Drug: Xamoterol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol (0.15 mg/Kg intravenous injection)
Study: 1968739
Drug: Xamoterol during
Normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol during dobutamine infusion
Study: 655186
Drug: Hydrochlorothiazide, 50
Normalized name: HydroCHLOROthiazide, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide, 50 mg daily (with 10 mg of amiloride or 50 mg of spironolactone)
Study: 655186
Drug: Acebutolol, 2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol, 2000 mg for 48 hours (in-hospital evaluation)
Study: 655186
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (acebutolol and diuretics)
Study: 17724529
Drug: Pantoprazol 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazol 40 mg/day for 12 weeks
Study: 16986228
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg once daily
Study: 24432037
Drug: Avanafil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avanafil (200 mg) 0.5 hours before NTG
Study: 24432037
Drug: Sildenafil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (100 mg) 0.5 hours before NTG
Study: 24432037
Drug: Sildenafil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (100 mg) 1 hour before NTG
Study: 20810219
Drug: Estrogen‐containing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen‐containing hormone therapy
Study: 12688320
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (HDMP) in Group B1
Study: 12688320
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose steroids in Group A2 and A3
Study: 9042991
Drug: Placebo, subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, subcutaneous injection 5 min before ingestion of a test meal
Study: 1607272
Drug: Quinidine bisulphate
Normalized name: quinidine bisulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine bisulphate 500 mg from Teva
Study: 1607272
Drug: Quinidine bisulphate
Normalized name: quinidine bisulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine bisulphate 250 mg from Teva
Study: 1607272
Drug: Short-acting quinidine
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting quinidine sulphate 200 mg
Study: 15709892
Drug: Fluoxetine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine + Cognitive Behavioural Therapy (CBT)
Study: 21878034
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) alone
Study: 15709892
Drug: No Fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Fluoxetine (placebo)
Study: 10485771
Drug: Intramuscular rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular rocuronium (1 mg/kg for infants, 1.8 mg/kg for children)
Study: 10485771
Drug: Intravenous rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rocuronium (0.45 mg/kg)
Study: 10485771
Drug: Intramuscular rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular rocuronium
Study: 8938532
Drug: Ribavirin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (1000 or 1200 mg/day for 24 weeks)
Study: 25210879
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of GLP‐1 (0.9 pmol/kg/min)
Study: 17512607
Drug: Olanzapine-Fluoxetine Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine-Fluoxetine Combination (OFC) (6/25, 6/50, or 12/50 mg/day)
Study: 8103703
Drug: Cetirizine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (15 mg single dose)
Study: 8542164
Drug: Placebo (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (7 days treatment)
Study: 1673975
Drug: Cetirizine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (single dose)
Study: 1673975
Drug: Cetirizine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (7 days treatment)
Study: 7284885
Drug: 6 ml
Normalized name: ethanol 0.6 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 ml of bupivacaine 0.5 per cent
Study: 21793047
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) via video teleconferencing (VT)
Study: 21793047
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) in-person modality
Study: 10967604
Drug: 73.5 mg
Normalized name: silymarin 73.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 73.5 mg RRR‐alpha‐tocopherol acetate
Study: 8695075
Drug: Ketorolac 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 0.75 mg/kg
Study: 20466223
Drug: Meperidine 1
Normalized name: meperidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 1 mg/kg
Study: 6434081
Drug: Vitamin D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin D2 25 micrograms daily
Study: 6434081
Drug: Alfacalcidol 0.5
Normalized name: alfacalcidol 0.5 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol 0.5 micrograms daily
Study: 24872684
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration (WBV) at 30 Hz and 3.2 g for 3 months
Study: 17688462
Drug: High-dose dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dopamine precursors in Parkinson's disease
Study: 12402427
Drug: Intraportal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraportal chemotherapy with 10 mg/body of mitomycin and 500 mg/m2 of 5-FU for 7 days followed by oral 5-FU
Study: 11219972
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 5-FU
Study: 12402427
Drug: Intraportal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraportal chemotherapy for stage III colorectal cancer
Study: 12063371
Drug: Intranasal mupirocin
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal mupirocin
Study: 2865422
Drug: Oral ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ketoconazole
Study: 9620106
Drug: Antifungal prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal prophylaxis
Study: 2107237
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose rt-PA (2 mg/kg body weight over 3 h)
Study: 2107237
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose rt-PA (1.25 mg/kg over 3 h)
Study: 2107237
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose rt-PA (2 mg/kg)
Study: 2107237
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose rt-PA (1.25 mg/kg)
Study: 31767184
Drug: Fresh blastocysts
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh blastocysts without treatment (Group 5)
Study: 28668998
Drug: Magnesium-Zinc-Calcium-Vitamin D
Normalized name: calcium carbonate / magnesium oxide / zinc oxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium-Zinc-Calcium-Vitamin D co-supplementation (100 mg magnesium, 4 mg zinc, 400 mg calcium, 200 IU vitamin D, twice a day for 12 weeks)
Study: 28668998
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice a day for 12 weeks)
Study: 20920179
Drug: Worsening of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Worsening of akathisia (measured by the Barnes Akathisia Scale) during the first two weeks of treatment
Study: 20920179
Drug: Worsening of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Worsening of symptoms of depression/anxiety (subscale score on the Positive and Negative Syndrome Scale) during the first two weeks of treatment
Study: 20920179
Drug: Lack of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lack of antipsychotic use in the prior year
Study: 17256807
Drug: Omeprazole (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (after dose adjustment)
Study: 12596444
Drug: OptiMAL test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: OptiMAL test for Plasmodium falciparum (sequential design)
Study: 12596444
Drug: OptiMAL test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: OptiMAL test for Plasmodium vivax (sequential design)
Study: 2761917
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon alpha‐2b (3 x 10(6) U (3 MU)/m2 daily for 3 weeks, total dose 63 MU/m2)
Study: 2761917
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon alpha‐2b
Study: 2761917
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon alpha‐2b
Study: 31264943
Drug: Donepezil (2.5‐10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (2.5‐10.0 mg per day)
Study: 10853843
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy followed by irradiation (CTRT)
Study: 8222816
Drug: Antireflux therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antireflux therapy
Study: 8222816
Drug: Distal esophageal
Normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal esophageal infusion of 0.1 N HCl
Study: 2419687
Drug: Mexiletine 200
Normalized name: mexiletine 200 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine 200 mg IMI
Study: 2419687
Drug: Mexiletine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine 300 mg IMI
Study: 2419687
Drug: Mexiletine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine 400 mg IMI
Study: 2419687
Drug: Mexiletine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine 500 mg IMI
Study: 27322164
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) TB drugs
Study: 27322164
Drug: Loose formulation
Normalized name: loose wheat smut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loose formulation (LF) TB treatment regimens
Study: 18598093
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg alone
Study: 15992513
Drug: Plant sterol
Normalized name: plant sterol complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol ester 1.6 g/day
Study: 15992513
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol ester 1.6 g/day
Study: 15992513
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol ester 2.6 g/day
Study: 12074224
Drug: Rotary preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotary preparation with diamond burs
Study: 12074224
Drug: Sonicflex 2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonicflex 2000 L/N (HS)
Study: 2706044
Drug: Moderate freshwater
Normalized name: FRESHWATER DRUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate freshwater fish diet (3.7 fish meals per week, about 1 g of n‐3 fatty acids daily)
Study: 790552
Drug: Ketoprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (200 mg daily)
Study: 796938
Drug: Aspirin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (4 g daily)
Study: 29846605
Drug: 14 day
Normalized name: Ponvory 14 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 day sequential therapy
Study: 27124695
Drug: Intensive glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glycemic control (IG, target 140 mg/dL)
Study: 27124695
Drug: Moderate glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate glycemic control (MG, target 180 mg/dL)
Study: 25412669
Drug: Preoperative electroacupuncture
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative electroacupuncture at PC6, ST36, and ST37 bilaterally with electrical stimulation twice a day for 20 min
Study: 25412669
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (routine treatment without electroacupuncture)
Study: 23138518
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (200 mg hydroxychloroquine sulfate)
Study: 23138518
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (200 mg hydroxychloroquine sulfate)
Study: 12121601
Drug: Twinrix vaccine
Normalized name: TWINRIX vaccine 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twinrix vaccine (combined hepatitis A and B vaccine) administered on a 0‐, 1‐ and 6‐month schedule
Study: 8943591
Drug: Morphine via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine via patient controlled analgesia and local cooling of the wound by an externally applied cooling pad
Study: 6177371
Drug: Heparin-Dihydroergotamine (DHE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-Dihydroergotamine (DHE)
Study: 17674518
Drug: Selenium enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium enriched food supplement based on spirulina
Study: 10710009
Drug: Ferrum H
Normalized name: Ferrum
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrum H (5x2ml intramuscular injections)
Study: 2264362
Drug: Parenteral immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral immunization with 'Influmun' from SSW Dresden, GDR
Study: 2264362
Drug: Oral immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunization with an inactivated influenza vaccine using enteric-coated capsules
Study: 7041579
Drug: Nylidrin HCl
Normalized name: nylidrin HCl
DrugBank: Nylidrin (DB06152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nylidrin HCl (3 mg)
Study: 18040527
Drug: Colchicine and
Normalized name: colchicine and probenecid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine and vitamin E therapy
Study: 9352981
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of streptokinase and alteplase
Study: 9352981
Drug: Irrespective of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrespective of treatment
Study: 28835513
Drug: pembrolizumab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab (2 mg/kg IV every 3 weeks)
Study: 28835513
Drug: pembrolizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab (10 mg/kg IV every 3 weeks)
Study: 28256066
Drug: docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel (75 mg/m2 every 3 weeks)
Study: 15610829
Drug: Naltrexone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone treatment (50 mg daily)
Study: 15695979
Drug: Cooperative group
Normalized name: cloperastine
DrugBank: Cloperastine (DB09002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooperative group trials for Stage IB 2 disease treated with radiation therapy
Study: 10629347
Drug: Glycine 0.5
Normalized name: GLYCINE 0.5 g in 100 g DENTAL PASTE, DENTIFRICE [CAREDO Treating Gingivitis Toothpastes 100g]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine 0.5 g/day
Study: 1353607
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg per day of didanosine
Study: 1353607
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg per day of didanosine
Study: 1353607
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg per day of zidovudine
Study: 6375804
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg metronidazole three times daily for seven days
Study: 6364329
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg metronidazole as a single dose
Study: 6375804
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg metronidazole on days 1 and 2
Study: 6375804
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg metronidazole on days 1 and 3
Study: 8730975
Drug: Allopurinol 50
Normalized name: allopurinol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 50 mg
Study: 30290598
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment and cognitive rehabilitation training
Study: 26965760
Drug: Higher salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher salt intake group (>=10.0 g/day, n=362)
Study: 20210592
Drug: Functional electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional electrical stimulation (FES) therapy